Back to Search Start Over

Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth

Authors :
Thibault Kervarrec
Bhavishya Sarma
Eva-Maria Sarosi
Carolin Schulte
Christian Adam
Sonja Hesbacher
David Schrama
Roland Houben
Sabine Popp
Department of Dermatology, Venerology and Allergology
Universitätsklinikum Würzburg
Département de Pathologie [CHRU Tours]
Université Francois Rabelais [Tours]-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
Infectiologie et Santé Publique (UMR ISP)
Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
This research was funded by grants from the German Cancer Aid (70112438) and the German Research Foundation (HO5280/2-2).
Université Francois Rabelais [Tours]-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Source :
Cancer Letters, Cancer Letters, Elsevier, 2022, 524, pp.259-267. ⟨10.1016/j.canlet.2021.10.031⟩
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

International audience; Merkel cell carcinoma is an aggressive skin cancer frequently caused by the Merkel cell polyomavirus (MCPyV). Since proliferation of MCPyV-positive MCC tumor cells strictly depends on expression of the virus-encoded T antigens (TA), these proteins theoretically represent ideal targets for different kinds of therapeutic approaches. Here we developed a cell-based assay to identify compounds which specifically inhibit growth of MCC cells by repressing TA expression. Applying this technique we screened a kinase inhibitor library and identified six compounds targeting glycogen synthase kinase 3 (GSK3) such as CHIR99021 as suppressors of TA transcription in MCC cells. Involvement of GSK3 alpha and -beta in the regulation of TA-expression was confirmed by combining GSK3A knockout with inducible GSK3B shRNA knockdown since double knockouts could not be generated. Finally, we demonstrate that CHIR99021 exhibits in vivo antitumor activity in an MCC xenograft mouse model suggesting GSK3 inhibitors as potential therapeutics for the treatment of MCC in the future.

Details

ISSN :
03043835
Volume :
524
Database :
OpenAIRE
Journal :
Cancer Letters
Accession number :
edsair.doi.dedup.....7eb6a40e2bbfcd1dce82fc131b873313
Full Text :
https://doi.org/10.1016/j.canlet.2021.10.031